SCHEMBL1684656

SCHEMBL1684656

Cc1ccc(Nc2nccc(-c3c(C)nc4ncccn34)n2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.65
GAA P10253 7/20 0.65
ALDH1A1 P00352 4/20 0.65
KDM4E B2RXH2 3/20 0.65
LMNA P02545 2/20 0.65
RAB9A P51151 2/20 0.65
CYP1A2 P05177 1/20 0.65
CYP3A4 P08684 1/20 0.65
CYP2D6 P10635 1/20 0.65
HPGD P15428 1/20 0.65
ALOX12 P18054 1/20 0.65
CYP2C19 P33261 1/20 0.65
CDK2 P24941 7/20 0.61
CDK4 P11802 4/20 0.61
CCNE1 P24864 3/20 0.61
MAPK1 P28482 4/20 0.55
HTT P42858 2/20 0.55
PKM P14618 2/20 0.53
POLB P06746 1/20 0.53
KDR P35968 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1684728 0.91 CDK2 (0.58) MAPTGAAALDH1A1KDM4ELMNA
SCHEMBL1684749 0.91 CDK2 (0.58) MAPTGAAALDH1A1KDM4ELMNA
SCHEMBL1684528 0.89 MAPT (0.67) MAPTGAAALDH1A1KDM4ELMNA
SCHEMBL1684609 0.89 MAPT (0.67) MAPTGAAALDH1A1KDM4ELMNA
SCHEMBL7980905 0.87 CDK2 (0.57) MAPTGAAALDH1A1KDM4ELMNA
SCHEMBL1684689 0.87 CDK2 (0.54) MAPTGAAALDH1A1KDM4ELMNA
SCHEMBL1684778 0.87 CDK2 (0.54) MAPTGAAALDH1A1KDM4ELMNA
SCHEMBL1684781 0.86 CDK2 (0.53) MAPTGAAALDH1A1KDM4ELMNA
SCHEMBL10251884 0.86 MAPK8 (0.56) MAPTGAAALDH1A1KDM4ELMNA
SCHEMBL700934 0.85 HDAC1 (0.57) MAPTGAAALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US disclosed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A MAPT 4026/4885GAA 3522/4885ALDH1A1 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.